Skip to main content

Merck & Co., Inc. Belsomra revenue

  • MRK · NYSE
  • Pharmaceuticals
  • S&P 500
$147.76+0.55%Close 13 Nov 2026 · Market value $361.6B

Belsomra revenue at Merck & Co., Inc. came to $49.0M for the quarter to 31 Dec 2025, up 8.9% from a year earlier.

As Merck & Co., Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 24 Feb 2026.

By quarter

$56.0MMar 2023$63.0MJun 2023$58.0MSep 2023$55.0MDec 2023$46.0MMar 2024$53.0MJun 2024$78.0MSep 2024$45.0MDec 2024$50.0MMar 2025$40.0MJun 2025$47.0MSep 2025$49.0MDec 2025
Merck & Co., Inc. Belsomra revenue, every reported period
Period endingBelsomra revenueChange on a yearFiled
31 Dec 2025$49.0Mup 8.9%24 Feb 2026
30 Sep 2025$47.0Mdown 39.7%5 Nov 2025
30 Jun 2025$40.0Mdown 24.5%5 Aug 2025
31 Mar 2025$50.0Mup 8.7%2 May 2025
31 Dec 2024$45.0Mdown 18.2%25 Feb 2025
30 Sep 2024$78.0Mup 34.5%6 Nov 2024
30 Jun 2024$53.0Mdown 15.9%5 Aug 2024
31 Mar 2024$46.0Mdown 17.9%3 May 2024
31 Dec 2023$55.0Mdown 6.8%26 Feb 2024
30 Sep 2023$58.0Mdown 6.5%3 Nov 2023
30 Jun 2023$63.0Mdown 8.7%7 Aug 2023
31 Mar 2023$56.0Mdown 18.8%5 May 2023
31 Dec 2022$59.0Mdown 26.2%24 Feb 2023
30 Sep 2022$62.0Mdown 23.5%3 Nov 2022
30 Jun 2022$69.0Mdown 11.5%5 Aug 2022
31 Mar 2022$69.0Mdown 12.7%5 May 2022
31 Dec 2021$80.0Mdown 3.6%25 Feb 2022
30 Sep 2021$81.0Munchanged5 Nov 2021
30 Jun 2021$78.0Mdown 7.1%9 Aug 2021
31 Mar 2021$79.0Munchanged5 May 2021
31 Dec 2020$83.0Munchanged25 Feb 2021
30 Sep 2020$81.0Mup 1.2%5 Nov 2020
30 Jun 2020$84.0Mup 10.5%5 Aug 2020
31 Mar 2020$79.0Mup 17.9%6 May 2020
31 Dec 2019$83.0Mup 20.3%26 Feb 2020
30 Sep 2019$80.0Mup 21.2%5 Nov 2019
30 Jun 2019$76.0Mup 7.0%6 Aug 2019
31 Mar 2019$67.0Mup 24.1%8 May 2019
31 Dec 2018$69.0M—27 Feb 2019
30 Sep 2018$66.0Mup 17.9%6 Nov 2018
30 Jun 2018$71.0Mup 36.5%7 Aug 2018
31 Mar 2018$54.0M—8 May 2018
30 Sep 2017$56.0M—7 Nov 2017
30 Jun 2017$52.0M—8 Aug 2017

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Merck & Co., Inc.: Keytruda revenue · Gardasil/Gardasil 9 revenue · Livestock revenue · Keytruda Qlex revenue · ProQuad/M-M-R II/Varivax revenue · Winrevair revenue · Companion Animal revenue · Lynparza alliance revenue · Prevymis revenue · Welireg revenue · Lenvima alliance revenue · Capvaxive revenue · RotaTeq revenue · Vaxneuvance revenue · Janumet revenue · Januvia revenue · Ohtuvayre revenue · Reblozyl alliance revenue · Bridion revenue · Adempas/Verquvo alliance revenue · Zerbaxa revenue · Adempas revenue · Delstrigo revenue · Isentress/Isentress HD revenue · financial statements

Every KPI and segment of MRK, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.